血脑屏障终于被突破了吗？
Has the blood-brain barrier finally been busted?
机构信息
University of Ottawa, Ottawa, ON, Canada K1H 8L6.
出版信息
Oncologist. 2024 Aug 5;29(8):645-647. doi: 10.1093/oncolo/oyae131.
Abstract
Faith in the blood-brain barrier has been remarkably resilient. This commentary questions its importance in the treatment of brain metastases.
摘要
人们对血脑屏障的信心一直很强。本文评论质疑了其在治疗脑转移瘤中的重要性。
相似文献
1
Has the blood-brain barrier finally been busted?血脑屏障终于被突破了吗？
Oncologist. 2024 Aug 5;29(8):645-647. doi: 10.1093/oncolo/oyae131.
2
Novel Treatment Approaches for Brain Tumour from a Blood-Brain Barrier Perspective.从血脑屏障角度看脑瘤的新治疗方法。
Handb Exp Pharmacol. 2022;273:351-364. doi: 10.1007/164_2020_408.
3
Blood-brain barrier.血脑屏障
J Neurosurg. 2014 Jan;120(1):290. doi: 10.3171/2013.6.JNS131197. Epub 2013 Nov 1.
4
Blood-brain barrier. Response.血脑屏障。反应。
J Neurosurg. 2014 Jan;120(1):291.
5
Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors.人类恶性脑肿瘤中的毛细血管超微结构与血脑屏障
J Neurosurg. 1970 Feb;32(2):127-44. doi: 10.3171/jns.1970.32.2.0127.
6
Strategies for overcoming the blood-brain barrier for the treatment of brain metastases.克服血脑屏障以治疗脑转移瘤的策略。
CNS Oncol. 2013 Jan;2(1):87-98. doi: 10.2217/cns.12.37.
7
Focusing on brain tumours and brain metastasis.专注于脑肿瘤和脑转移瘤。
Nat Rev Cancer. 2020 Jan;20(1):1. doi: 10.1038/s41568-019-0232-7.
8
Advances in Intraarterial Chemotherapy Delivery Strategies and Blood-Brain Barrier Disruption.动脉内化疗输送策略和血脑屏障破坏的进展。
Neurosurg Clin N Am. 2022 Apr;33(2):219-223. doi: 10.1016/j.nec.2022.01.001.
9
[Tracer studies with radioactive-labelled cyclophosphamide in brain tumors].[放射性标记环磷酰胺在脑肿瘤中的示踪研究]
Acta Neurochir (Wien). 1965;13(3):441-56. doi: 10.1007/BF02074426.
10
Changes in histochemical staining of brain tumor blood vessels associated with increasing malignancy.脑肿瘤血管的组织化学染色变化与恶性程度增加相关。
Acta Neuropathol. 1969;14(3):161-73. doi: 10.1007/BF00685296.
引用本文的文献
1
Resistance mutations and the blood-brain barrier: Key challenges in targeted treatment of brain metastatic non-small cell lung cancer.耐药突变与血脑屏障：脑转移非小细胞肺癌靶向治疗中的关键挑战
Acta Pharm Sin B. 2025 Aug;15(8):3833-3851. doi: 10.1016/j.apsb.2025.06.002. Epub 2025 Jun 7.
2
Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs.第一代/第二代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）耐药后出现各种T790M突变的EGFR突变晚期非小细胞肺癌中使用第三代EGFR-TKIs的专家共识
Ther Adv Med Oncol. 2024 Oct 17;16:17588359241289648. doi: 10.1177/17588359241289648. eCollection 2024.
本文引用的文献
1
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.CNS 疗效：奥希替尼联合或不联合化疗用于表皮生长因子受体突变的晚期非小细胞肺癌。
J Clin Oncol. 2024 Mar 1;42(7):808-820. doi: 10.1200/JCO.23.02219. Epub 2023 Dec 2.
2
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.HERTHENA-Lung01 研究：曲妥珠单抗德鲁替康（HER3-DXd）在表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）和铂类化疗治疗后的表皮生长因子受体突变型非小细胞肺癌中的 II 期研究。
J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10.
3
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康治疗 HER2 阳性乳腺癌伴脑转移：一项单臂、2 期临床试验。
Nat Med. 2022 Sep;28(9):1840-1847. doi: 10.1038/s41591-022-01935-8. Epub 2022 Aug 8.
4
Blood-Brain Barrier Alterations and Edema Formation in Different Brain Mass Lesions.不同脑实质病变中的血脑屏障改变与水肿形成
Front Cell Neurosci. 2022 Jul 15;16:922181. doi: 10.3389/fncel.2022.922181. eCollection 2022.
5
Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance.脑肿瘤中的血脑屏障：生物学及临床相关性
Int J Mol Sci. 2021 Nov 23;22(23):12654. doi: 10.3390/ijms222312654.
6
The need for speed in advanced non-small cell lung cancer: A population kinetics assessment.晚期非小细胞肺癌中对速度的需求：群体动力学评估。
Cancer Med. 2021 Dec;10(24):9040-9046. doi: 10.1002/cam4.4411. Epub 2021 Nov 11.
7
Brain Metastases Status and Immunotherapy Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis.脑转移状态与晚期肺癌免疫治疗疗效：系统评价和荟萃分析。
Front Immunol. 2021 Jul 14;12:669398. doi: 10.3389/fimmu.2021.669398. eCollection 2021.
8
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.FIR：在 PD-L1 选择的 NSCLC 患者中进行的 Atezolizumab Ⅱ期开放标签研究的疗效、安全性和生物标志物分析。
J Thorac Oncol. 2018 Nov;13(11):1733-1742. doi: 10.1016/j.jtho.2018.05.004.
9
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.阿来替尼对比克唑替尼用于未经治疗的 ALK 阳性非小细胞肺癌。
N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.
10
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.ALK 重排肺癌对第一代和第二代 ALK 抑制剂耐药的分子机制
Cancer Discov. 2016 Oct;6(10):1118-1133. doi: 10.1158/2159-8290.CD-16-0596. Epub 2016 Jul 18.
Zotero 插件